Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels.
Staudacher K
,
Staudacher I
,
Ficker E
,
Seyler C
,
Gierten J
,
Kisselbach J
,
Rahm AK
,
Trappe K
,
Schweizer PA
,
Becker R
,
Katus HA
,
Thomas D
.
???displayArticle.abstract???
BACKGROUND AND PURPOSE: Human K(2P) 3.1 (TASK1) channels represent potential targets for pharmacological management of atrial fibrillation. K(2P) channels control excitability by stabilizing membrane potential and by expediting repolarization. In the heart, inhibition of K(2P) currents by class III antiarrhythmic drugs results in action potential prolongation and suppression of electrical automaticity. Carvedilol exerts antiarrhythmic activity and suppresses atrial fibrillation following cardiac surgery or cardioversion. The objective of this study was to investigate acute effects of carvedilol on human K(2P) 3.1 (hK(2P) 3.1) channels.
EXPERIMENTAL APPROACH: Two-electrode voltage clamp and whole-cell patch clamp electrophysiology was used to record hK(2P) 3.1 currents from Xenopus oocytes, Chinese hamster ovary (CHO) cells and human pulmonary artery smooth muscle cells (hPASMC).
KEY RESULTS: Carvedilol concentration-dependently inhibited hK(2P) 3.1 currents in Xenopus oocytes (IC(50) = 3.8 µM) and in mammalian CHO cells (IC(50) = 0.83 µM). In addition, carvedilol sensitivity of native I(K2P3.1) was demonstrated in hPASMC. Channels were blocked in open and closed states in frequency-dependent fashion, resulting in resting membrane potential depolarization by 7.7 mV. Carvedilol shifted the current-voltage (I-V) relationship by -6.9 mV towards hyperpolarized potentials. Open rectification, characteristic of K(2P) currents, was not affected.
CONCLUSIONS AND IMPLICATIONS: The antiarrhythmic drug carvedilol targets hK(2P) 3.1 background channels. We propose that cardiac hK(2P) 3.1 current blockade may suppress electrical automaticity, prolong atrial refractoriness and contribute to the class III antiarrhythmic action in patients treated with the drug.
,
Guide to Receptors and Channels (GRAC), 4th Edition.
2009, Pubmed
,
Guide to Receptors and Channels (GRAC), 4th Edition.
2009,
Pubmed
Acikel,
Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery.
2008,
Pubmed
Bayliss,
The TASK family: two-pore domain background K+ channels.
2003,
Pubmed
Cheng,
Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes.
1999,
Pubmed
Cotten,
The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration.
2006,
Pubmed
,
Xenbase
Deng,
Effects of carvedilol on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes.
2007,
Pubmed
Dobrev,
New antiarrhythmic drugs for treatment of atrial fibrillation.
2010,
Pubmed
Donner,
Functional role of TASK-1 in the heart: studies in TASK-1-deficient mice show prolonged cardiac repolarization and reduced heart rate variability.
2011,
Pubmed
Duprat,
TASK, a human background K+ channel to sense external pH variations near physiological pH.
1997,
Pubmed
,
Xenbase
El-Sherif,
Electrophysiologic effects of carvedilol: is carvedilol an antiarrhythmic agent?
2005,
Pubmed
Enyedi,
Molecular background of leak K+ currents: two-pore domain potassium channels.
2010,
Pubmed
Gierten,
Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein.
2008,
Pubmed
,
Xenbase
Gierten,
The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.
2010,
Pubmed
,
Xenbase
Goldstein,
Potassium leak channels and the KCNK family of two-P-domain subunits.
2001,
Pubmed
Goldstein,
International Union of Pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels.
2005,
Pubmed
Gurney,
Two-pore domain K channel, TASK-1, in pulmonary artery smooth muscle cells.
2003,
Pubmed
Haghjoo,
Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol.
2007,
Pubmed
Honoré,
An intracellular proton sensor commands lipid- and mechano-gating of the K(+) channel TREK-1.
2002,
Pubmed
Kanoupakis,
Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation.
2004,
Pubmed
Kanoupakis,
Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy.
2008,
Pubmed
Karle,
Antiarrhythmic drug carvedilol inhibits HERG potassium channels.
2001,
Pubmed
,
Xenbase
Katritsis,
Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation.
2003,
Pubmed
Kawakami,
Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy.
2006,
Pubmed
Kiesecker,
Regulation of cardiac inwardly rectifying potassium current IK1 and Kir2.x channels by endothelin-1.
2006,
Pubmed
,
Xenbase
Kindler,
Local anesthetic inhibition of baseline potassium channels with two pore domains in tandem.
1999,
Pubmed
,
Xenbase
Leonoudakis,
An open rectifier potassium channel with two pore domains in tandem cloned from rat cerebellum.
1998,
Pubmed
,
Xenbase
Lopes,
Proton block and voltage gating are potassium-dependent in the cardiac leak channel Kcnk3.
2000,
Pubmed
,
Xenbase
Maingret,
The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1.
2001,
Pubmed
Merritt,
Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation.
2003,
Pubmed
Nattel,
Atrial remodeling and atrial fibrillation: mechanisms and implications.
2008,
Pubmed
Olschewski,
Impact of TASK-1 in human pulmonary artery smooth muscle cells.
2006,
Pubmed
Patel,
Properties and modulation of mammalian 2P domain K+ channels.
2001,
Pubmed
Patel,
Inhalational anesthetics activate two-pore-domain background K+ channels.
1999,
Pubmed
Poole-Wilson,
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
2003,
Pubmed
Putzke,
The acid-sensitive potassium channel TASK-1 in rat cardiac muscle.
2007,
Pubmed
,
Xenbase
Putzke,
Differential effects of volatile and intravenous anesthetics on the activity of human TASK-1.
2007,
Pubmed
,
Xenbase
Ramaswamy,
Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study.
2003,
Pubmed
Ravens,
Novel pharmacological approaches for antiarrhythmic therapy.
2010,
Pubmed
Remme,
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
2007,
Pubmed
Ruffolo,
Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
1997,
Pubmed
Sirois,
The TASK-1 two-pore domain K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics.
2000,
Pubmed
Thomas,
High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
2001,
Pubmed
,
Xenbase
Thomas,
Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A.
1999,
Pubmed
,
Xenbase
Thomas,
Alternative translation initiation in rat brain yields K2P2.1 potassium channels permeable to sodium.
2008,
Pubmed
,
Xenbase
Tsuboi,
Postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting.
2008,
Pubmed
Yokoyama,
Electrophysiological effects of carvedilol on rabbit heart pacemaker cells.
2007,
Pubmed
